Faith E Davies MD

Professor Of Medicine Director, Myeloma Clinical Program

240 E 38th StNew York, NY 10016
Phone+1 212-731-5180
Fax+1 212-731-5506

Dr. Davies is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Davies' full profile Already have an account?

Education & Training

The University of Wales College of MedicineClass of 1992

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NY State Medical License 2021 - 2026
AR State Medical License 2014 - 2019

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017

Clinical Trials

UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus
COMPLETED
PHASE2
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy Start of enrollment: 2017 Apr 01
WITHDRAWN
PHASE2
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy Start of enrollment: 2017 Jul 01
ACTIVE_NOT_RECRUITING
PHASE2

Publications & Presentations

PubMed

Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.
Carlyn Rose Tan, Lucio Gordan, Joshua Richter, Rachel DiLeo, Prerna Mewawalla
Future Oncology. 2026-08-01
Dual target combination therapy demonstrates promise in extramedullary myeloma.
James Behrmann, Faith E Davies
Translational Cancer Research. 2026-07-31
1 citations
Study of NSD2 using a dTAG system reveals its molecular mechanism and oncogenic implications in t(4;14) multiple myeloma.
Yubao Wang, Sanxiong Liu, Hussein Ghamlouch, Dylan C Gagler, Patrick Blaney
Blood. 2026-06-11

Journal Articles

Sub-Clonal TP53 Copy Number Is Associated with Prognosis in Multiple Myeloma
Faith Davies, MD, Blood
Characterisation of Immunoparesis in Newly Diagnosed Myeloma and Its Impact on Progression-Free and Overall Survival in Both Old and Recent Myeloma Trials
Faith Davies, MD, Nature

Abstracts/Posters

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IR...
Faith E. Davies, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Spectrum of Exomic Mutation in Elderly Myeloma Differs Substantially from Patients at Younger Ages Consistent with a Different Evolutionary Trajectory to Full Blow...
Faith E. Davies, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
Faith E. Davies, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Current Obstacles in Myeloma Management: Debating the Evidence
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Characterisation of Long-Term Responders to First-Line Myeloma Therapy – Results from the UK Myeloma IX and XI Trials
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) – Effectiveness in Routine Clinical Practice Is Similar to t...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Clinical Challenges: Staying up to Date on Immunotherapy in Multiple MyelomaJanuary 4th, 2022
Leading Myeloma Experts to Join New Center for Blood Cancers at NYU Langone HealthApril 4th, 2019
Could a Unique MRI Scan Improve Treatments for Bone Marrow Cancer?February 12th, 2016

Grant Support

Investigating the role of incretin mimetics in reducing the risk of development and progression of multiple myeloma and its precursor conditionsNEW YORK UNIVERSITY SCHOOL OF MEDICINE2026–2028